MICROPORT SCIENTIFIC CORPORATION Financials MicroPort Scientific Corporation
Equities
853
KYG608371046
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.06 HKD | +8.12% |
|
+6.33% | -16.15% |
| May. 01 | MicroPort Scientific's 2023 Loss Widens Despite Revenue Growth | MT |
| Apr. 09 | Nomura Adjusts MicroPort Scientific’s Price Target to HK$6.71 From HK$7.19, Keeps at Neutral | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,915 | 9,653 | 6,537 | 4,793 | 1,975 | 1,530 | - | - |
| Enterprise Value (EV) 1 | 2,093 | 8,947 | 6,026 | 4,881 | 1,975 | 1,825 | 1,749 | 2,321 |
| P/E ratio | 59.8 x | -49.3 x | -22 x | -10.9 x | -4.12 x | -6.99 x | -9.54 x | 27.8 x |
| Yield | 0.58% | 0.1% | 0.15% | - | - | - | - | - |
| Capitalization / Revenue | 2.41 x | 14.9 x | 8.39 x | 5.7 x | 2.08 x | 1.29 x | 1.1 x | 0.96 x |
| EV / Revenue | 2.64 x | 13.8 x | 7.74 x | 5.81 x | 2.08 x | 1.54 x | 1.26 x | 1.45 x |
| EV / EBITDA | 23.4 x | -92.5 x | -28.5 x | -13 x | -5.14 x | -14.7 x | -27.9 x | - |
| EV / FCF | -29.7 x | -70.6 x | -12.6 x | -8.05 x | - | -6.47 x | -6.27 x | 26.1 x |
| FCF Yield | -3.37% | -1.42% | -7.95% | -12.4% | - | -15.5% | -15.9% | 3.84% |
| Price to Book | 3.62 x | 8.59 x | 4.42 x | 4.23 x | - | 2.02 x | 1.74 x | 2.98 x |
| Nbr of stocks (in thousands) | 1,616,587 | 1,783,923 | 1,794,276 | 1,821,352 | 1,831,722 | 1,831,722 | - | - |
| Reference price 2 | 1.185 | 5.411 | 3.643 | 2.631 | 1.078 | 0.8353 | 0.8353 | 0.8353 |
| Announcement Date | 3/30/20 | 3/30/21 | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 793.5 | 648.7 | 778.6 | 840.8 | 950.7 | 1,184 | 1,390 | 1,599 |
| EBITDA 1 | 89.64 | -96.74 | -211.1 | -374.6 | -384.6 | -124.4 | -62.63 | - |
| EBIT 1 | 28.46 | -167.6 | -293.6 | -507 | -516.2 | -150.1 | -18.5 | 157.8 |
| Operating Margin | 3.59% | -25.83% | -37.71% | -60.29% | -54.29% | -12.68% | -1.33% | 9.87% |
| Earnings before Tax (EBT) 1 | 63.21 | -212.9 | -337.3 | -581.5 | -626.5 | -273.9 | -262.6 | 37.14 |
| Net income 1 | 46.28 | -191.3 | -276.5 | -436.5 | -477.6 | -209.1 | -177.7 | 46.77 |
| Net margin | 5.83% | -29.48% | -35.51% | -51.91% | -50.24% | -17.66% | -12.79% | 2.93% |
| EPS 2 | 0.0198 | -0.1097 | -0.1654 | -0.2408 | -0.2619 | -0.1195 | -0.0875 | 0.0300 |
| Free Cash Flow 1 | -70.59 | -126.7 | -479.3 | -606.6 | - | -282 | -278.7 | 89 |
| FCF margin | -8.9% | -19.53% | -61.55% | -72.14% | - | -23.82% | -20.05% | 5.57% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 190.29% |
| Dividend per Share 2 | 0.006840 | 0.005530 | 0.005490 | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/30/21 | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2023 S1 |
|---|---|---|
| Net sales 1 | 405 | 482.6 |
| EBITDA | - | - |
| EBIT 1 | -218.6 | -164.6 |
| Operating Margin | -53.98% | -34.11% |
| Earnings before Tax (EBT) 1 | -247.8 | -206.2 |
| Net income 1 | -198.1 | -162.6 |
| Net margin | -48.92% | -33.7% |
| EPS | - | - |
| Dividend per Share | - | - |
| Announcement Date | 8/30/22 | 8/30/23 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 178 | - | - | 88.6 | - | 295 | 218 | 791 |
| Net Cash position 1 | - | 706 | 511 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.985 x | - | - | -0.2366 x | - | -2.372 x | -3.488 x | - |
| Free Cash Flow 1 | -70.6 | -127 | -479 | -607 | - | -282 | -279 | 89 |
| ROE (net income / shareholders' equity) | 9.62% | -23.2% | -21.1% | -33.2% | - | -29.4% | -17% | 9.65% |
| ROA (Net income/ Total Assets) | 3.22% | -9.41% | -8.07% | -10.4% | - | -4.2% | -1.67% | - |
| Assets 1 | 1,436 | 2,034 | 3,425 | 4,187 | - | 4,979 | 10,674 | - |
| Book Value Per Share 2 | 0.3300 | 0.6300 | 0.8200 | 0.6200 | - | 0.4100 | 0.4800 | 0.2800 |
| Cash Flow per Share 2 | 0.0200 | -0.0100 | -0.1400 | -0.1900 | - | -0.0500 | -0.0200 | - |
| Capex 1 | 97 | 104 | 248 | 263 | - | 168 | 126 | 140 |
| Capex / Sales | 12.23% | 15.96% | 31.84% | 31.31% | - | 14.15% | 9.07% | 8.76% |
| Announcement Date | 3/30/20 | 3/30/21 | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
0.8353
USD
Average target price
1.714
USD
Spread / Average Target
+105.19%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.15% | 1.56B | |
| +8.07% | 219B | |
| +7.87% | 184B | |
| +12.75% | 138B | |
| -1.37% | 62.54B | |
| +4.88% | 52.22B | |
| +11.59% | 51.73B | |
| +2.71% | 41.4B | |
| +4.90% | 37.17B | |
| +23.75% | 31.76B |
- Stock Market
- Equities
- 853 Stock
- Financials MicroPort Scientific Corporation